

1 July 2010

To the media,

GlaxoSmithKline K.K.  
Mitsubishi Tanabe Pharma Corporation

**GlaxoSmithKline and Mitsubishi Tanabe Pharma Corporation  
Terminates co-promotion of *Adoair*<sup>®</sup>, the combination drug for  
asthma and COPD**

GlaxoSmithKline K.K. (Head Office: Shibuya-ku, Tokyo, President: Philippe Fauchet, hereinafter referred to as GSK) and Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka, President: Michihiro Tsuchiya, hereinafter referred to as Mitsubishi Tanabe) announce that they have agreed to terminate, as of the end of July 2010, the co-promotion of *Adoair*<sup>®</sup> (salmeterol xinafoate/fluticasone propionate ester), the combination drug for asthma and chronic obstructive pulmonary disease (COPD) that they have been co-promoting since April 2009.

Notification to medical institutions will start from today (1 July) and GSK will continue to conduct information providing activities from August 2010.

The primary goal of the co-promotion between GSK and Mitsubishi Tanabe was to provide the latest treatment information to medical institutions as quickly as possible in order to improve the symptoms and breathing function of the estimated 5.3 million COPD patients in Japan. The day when patients could do what they wanted to do without being conscious of their disease was named "Good Days" and both companies strived to contribute toward increasing these days for patients.

Through this alliance, *Adoair*<sup>®</sup> became highly recognised by medical institutions as the leading product for treating asthma and COPD.

As the leading company of the respiratory area, GSK remains committed to further make *Adoair*<sup>®</sup> available to patients in need. Mitsubishi Tanabe is committed to further growing its mainstay products such as Remicade.

<Media enquiry>  
GlaxoSmithKline K.K.  
Tel: 03-5786-5030

Mitsubishi Tanabe Pharma Corporation  
Tel: 06-6205-5211